Pasar al contenido principal

CARACTERIZACION FUNCIONAL DE MUTACIONES EN GENES CONDUCTORES DEL CANCER IMPLICADOS EN MADURACION DEL RNA

PID2020-117185RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE OVIEDO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  • Nadeu, Ferran
  • Massoni-Badosa, Ramon
  • Ruiz Gil, Sara
  • Marchese, Domenica, 1986-
  • López Bigas, Núria
  • Gut, Ivo Glynne
  • Heyn, Holger
  • Campo, Elias
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high-B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT., This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR-736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundació La Marató de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigación Biomédica en Red Cáncer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovación (PID2020-117185RB-I00 to X.S.P.), the Fundación Asociación Española Contra el Cáncer (FUNCAR-PRYGN211258SUÁR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5 × 1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya. This work was partially developed at the Center Esther Koplowitz (Barcelona, Spain).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

  • Royo, Romina
  • Magnano, Laura
  • Delgado González, Julio
  • Ruiz Gil, Sara
  • Gelpí, Josep Lluís
  • Heyn, Holger
  • Taylor, Malcom A.
  • Stankovic, Tatjana
  • Puente, Xosé S.
  • Nadeu, Ferran
  • Campo, Elias
The authors thank the Hematopathology Collection registered at the Biobank of Hospital Clínic—Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) as well as Sílvia Martín for the technical support. This study was supported by the “la Caixa” Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to EC), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (810287, BCLLatlas, to EC, and HH), CERCA Program/Generalitat de Catalunya, Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-1142 (to EC), CIBERONC (CB16/12/00225 to EC), Ministerio de Ciencia e Innovación PID2020-117185RB-I00 (to XSP), FEDER: European Regional Development Fund “Una manera de hacer Europa”, and Fundación Asociación Española Contra el Cáncer FUNCAR-PRYGN211258SUÁR (to XSP). The authors thankfully acknowledge the computer resources at MareNostrum4 and the technical support provided by Barcelona Supercomputing Center (RES activity BCV-2018-3-0001). FN acknowledge research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, Grant Number 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, Grant Number RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukemia 2021–2022, Grant Number LADY_TATA_21_3223). EC is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” (ICREA) of the Generalitat de Catalunya. This work was partially developed at the Centre Esther Koplowitz (CEK, Barcelona, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  • Nadeu, Ferran
  • Royo, Romina
  • Massoni-Badosa, Ramon
  • Playa-Albinyana, Heribert
  • Garcia-Torre, Beatriz
  • Duran-Ferrer, Martí
  • Dawson, Kevin J.
  • Kulis, Marta
  • Diaz-Navarro, Ander
  • Villamor, Neus
  • Melero, Juan L.
  • Chapaprieta, Vicente
  • Dueso-Barroso, Ana
  • Delgado, Julio
  • Moia, Riccardo
  • Ruiz-Gil, Sara
  • Marchese, Domenica
  • Giró, Ariadna
  • Verdaguer-Dot, Núria
  • Romo, Mónica
  • Clot, Guillem
  • Rozman, María
  • Frigola, Gerard
  • Rivas-Delgado, Alfredo
  • Baumann, Tycho
  • Alcoceba, Miguel
  • González, Marcos
  • Climent, Fina
  • Abrisqueta, Pau
  • Castellví, Josep
  • Bosch, Francesc
  • Aymerich, Marta
  • Enjuanes, Anna
  • Ruiz-Gaspà, Sílvia
  • López-Guillermo, Armando
  • Jares, Pedro
  • Beà, Silvia
  • Capella-Gutiérrez, Salvador
  • Gelpí, Josep Lluis
  • López-Bigas, Nuria
  • Torrents, David
  • Campbell, Peter J.
  • Gut, Ivo
  • Rossi, Davide
  • Gaidano, Gianluca
  • Puente, Xose S.
  • García-Roves, Pablo M.
  • Colomer, Dolors
  • Heyn, Holger
  • Maura, Francesco
  • Martín-Subero, José Ignacio
  • Campo, Elías
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high–B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT., This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40- 11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/ AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundació La Marató de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigación Biomédica en Red Cáncer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovación (PID2020-117185RB-I00 to X.S.P.), the Fundación Asociación Española Contra el Cáncer (FUNCAR-PRYGN211258SUÁR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5×1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML

  • Bousquets-Muñoz, Pablo
  • Molina, Oscar
  • Varela, Ignacio
  • Álvarez-Eguiluz, Ángel
  • Gómez Peris, Ana
  • Sánchez, Elena G.
  • Balbín, Milagros
  • Ruano, David
  • Ramírez-Orellana, Manuel
  • Puente, Xose S.
  • Menéndez, Pablo
Acute leukemia is the most frequently diagnosed malignancy in childhood, with acute lymphoblastic leukemia (ALL) comprising approximately 80% of cases in children aged 0–18 years, and acute myeloid leukemia (AML) accounting for approximately 15–20% [1]. The early onset (0–10 years) of most childhood acute leukemias and the high concordance rate among monozygotic twins suggest a prenatal origin of the disease [1]. Indeed, the presence of preleukemic precursors in cord blood (CB) samples or Guthrie blood spots from children who later developed acute leukemia has been demonstrated in several studies [2, 3]. However, this has mainly been demonstrated experimentally for the most common cytogenetic subtypes, particularly in ALL., This research was partially supported by a donation from the patient’s family and Heroga Fertilizantes. Research in PM’s laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), the H2020 EU program (101057250-CANCERNA), the MINECO (PID2022-142966OB-I00/ MCIN/AEI/10.13039/501100011033 and Feder Funds), the MINECO/European Union NextGenerationEU (CPP2021-008508, CPP2022-009759); the Deutsche José Carreras Leukämie-Stiftung (DJCLS15R/2021 and DJCLS 02R/2023), the Spanish Association Against Cancer (AECC, PRYGN234975MENE) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Research in XSP’s laboratory is supported by Ministerio de Ciencia e Innovación (PID2020-117185RB-I00); the Spanish Association Against Cancer (AECC); Centro de Investigación Biomédica en Red Cáncer (CIBERONC); “La Caixa” Foundation CLLSYSTEMS (HR22-00172), European Union NextGenerationEU/Mecanismo para la Recuperación y la Resilencia (MRR)/PRTR and the Instituto de Salud Carlos III (ISCIII) (PMP21/00015). OM and TV-H were supported by an investigator award from AECC (INVES211226MOLI and INVES223069VELA, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms

  • Nadeu, Ferran
  • Shuai, Shimin
  • Clot, Guillem
  • Hilton, Laura K.
  • Diaz-Navarro, Ander
  • Martín, Silvia
  • Royo, Romina
  • Baumann, Tycho
  • Kulis, Marta
  • López-Oreja, Irene
  • Cossio, Manuel
  • Lu, Junyan
  • Ljungström, V.
  • Young, Emma
  • Plevova, Karla
  • Knisbacher, Binyamin A.
  • Lin, Ziao
  • Hahn, Cynthia K.
  • Bousquets, Pablo
  • Alcoceba, Miguel
  • González, Marcos
  • Colado, Enrique
  • Payer, Ángel R.
  • Aymerich, Marta
  • Terol, María José
  • Rivas-Delgado, Alfredo
  • Enjuanes, Anna
  • Ruiz-Gaspà, Sílvia
  • Chatzikonstantinou, Thomas
  • Hägerstrand, Daniel
  • Jylhä, Cecilia
  • Skaftason, Aron
  • Mansouri, Larry
  • Stranska, Kamila
  • Doubek, Michael
  • Gastel-Mol, Ellen J. van
  • Davis, Zadie
  • Walewska, Renata
  • Scarfò, Lydia
  • Trentin, Livio
  • Visentin, Andrea
  • Parikh, Sameer A.
  • Rabe, Kari G.
  • Moia, Riccardo
  • Armand, Marine
  • Rossi, Davide
  • Davi, Frédéric
  • Gaidano, Gianluca
  • Kay, Neil E.
  • Shanafelt, Tait D.
  • Ghia, Paolo
  • Oscier, David
  • Langerak, Anton W.
  • Beà, Silvia
  • López-Guillermo, Armando
  • Neuberg, Donna
  • Wu, Catherine J.
  • Getz, Gad
  • Pospisilova, Sarka
  • Stamatopoulos, Kostas
  • Rosenquist, Richard
  • Huber, Wolfgang
  • Zenz, Thorsten
  • Colomer, Dolors
  • Martín-Subero, José Ignacio
  • Delgado, Julio
  • Morin, Ryan D.
  • Stein, Lincoln D.
  • Puente, Xose S.
  • Campo, Elías
Recurrent mutations in the third base of U1 spliceosomal RNA responsible for marked splicing and expression abnormalities have been described in chronic lymphocytic leukemia (CLL) and some solid tumors. However, the clinical significance of these mutations in large and independent CLL cohorts as well as their presence in other B-cell neoplasms is unknown. Here we characterized U1 mutations in 1670 CLL and 363 mature B-cell lymphomas. We confirmed that the g.3A>C U1 mutation is found in 3.5% of CLL, which conferred rapid disease progression independently of the main biological and clinical prognostic markers of the disease. Additionally, a recurrent g.9C>T mutation was found in 1.5% of CLL causing downstream splicing alterations and associated with adverse prognosis. We also identified a g.4C>T mutation in 10% of diffuse large B-cell lymphomas of the germinal center subtype and a g.7A>G mutation in 30% of EBV-negative Burkitt lymphomas, both of which altered the splicing pattern of multiple genes. This study reveals novel, recurrent, and tumor-specific U1 mutations in mature B-cell neoplasms with biological and prognostic implications, thus establishing U1 as a novel pan-B-cell malignancy driver gene., This study was supported by the “la Caixa” Foundation (CLLEvolution - LCF/PR/HR17/52150017 [HR17-00221LCF] and CLLSYSTEMS - LCF/PR/HR22/52420015 [HR22-00172] Health Research 2017 and 2022 Programs, to ECa), the Ministry of Science and Innovation (MCIN)/AEI/10.13039/501100011033 and the European Regional Development Fund (FEDER) “Una manera de hacer Europa” (PID2021-123054OB-I00, to ECa), the National Institute of Health “Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma” (P01CA229100 to ECa), Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 and 2021-SGR-01172 to ECa), and CERCA Programme-Generalitat de Catalunya (to ECa). FN acknowledges research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223), and Fundación Española de Hematología y Hemoterapia (FEHH) (FEHH_BECAS24_01 co-financed by AstraZeneca). SS was supported by the National Natural Science Foundation of China (Grant No. 82270239 and 32200487), Shenzhen Medical Research Funds (Grant No. A2303044), the Shenzhen Municipal Science and Technology Innovation Council (Grant No. JCYJ20220530115207016), and Center for Computational Science and Engineering at Southern University of Science and Technology (Shenzhen, China). AD-N is supported by the Department of Education of the Basque Government (grant number PRE_2017_1_0100). AR-D was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). KP, KStr, MD, and SP acknowledge financial support from the Ministry of Health of the Czech Republic under the project of the conceptual development of research organization FNBr 65269705 and the project AZV NU21-08-00237, further, they acknowledge support from the Ministry of Education, Youth and Sports of the Czech Republic within the European Regional Development Fund Project “A-C-G-T” No. CZ.02.1.01/0.0/0.0/16_026/0008448 and the National Institute for Cancer Research, Programme EXCELES, No. LX22NPO5102, co-funded by the European Union – Next Generation EU. GGa acknowledges support from AIRC 5 ×1000 project No. 21198, Milan, Italy. PG acknowledges support from Associazione Italiana per la ricerca sul cancro (AIRC) under 5 per Mille 2018—ID. 21198 program—P.I. Roberto Foà, G.L. Paolo Ghia, G. RRos is supported by the Science for Life Laboratory (SciLifeLab), the Swedish Cancer Society, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Karolinska Institutet, Karolinska University Hospital, and Radiumhemmets Forskningsfonder, Stockholm, Sweden. For patients analyzed at Karolinska Institutet, sequencing was performed by the SNP&SEQ Technology Platform in Uppsala. The facility is part of the National Genomics Infrastructure (NGI) Sweden and SciLifeLab. The SNP&SEQ Platform is also supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. SAP, KGR, and NEK acknowledge that the conduct of the Mayo Clinic research was supported in part by the Henry J. Predolin Foundation. XSP is supported by Ministerio de Ciencia e Innovación (PID2020-117185RB-I00) and Fundación Asociación Española Contra el Cáncer (AECC). ECa is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” (ICREA) of the Generalitat de Catalunya. This work was partially developed at the Centre Esther Koplowitz (CEK, Barcelona, Spain)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

  • Royo, Romina
  • Magnano, Laura
  • Delgado González, Julio
  • Ruiz Gil, Sara
  • Gelpí, Josep Lluís
  • Heyn, Holger
  • Taylor, Malcom A.
  • Stankovic, Tatjana
  • Puente, Xosé S.
  • Nadeu, Ferran
  • Campo, Elias
The authors thank the Hematopathology Collection registered at the Biobank of Hospital Clínic—Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) as well as Sílvia Martín for the technical support. This study was supported by the “la Caixa” Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to EC), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (810287, BCLLatlas, to EC, and HH), CERCA Program/Generalitat de Catalunya, Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-1142 (to EC), CIBERONC (CB16/12/00225 to EC), Ministerio de Ciencia e Innovación PID2020-117185RB-I00 (to XSP), FEDER: European Regional Development Fund “Una manera de hacer Europa”, and Fundación Asociación Española Contra el Cáncer FUNCAR-PRYGN211258SUÁR (to XSP). The authors thankfully acknowledge the computer resources at MareNostrum4 and the technical support provided by Barcelona Supercomputing Center (RES activity BCV-2018-3-0001). FN acknowledge research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, Grant Number 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, Grant Number RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukemia 2021–2022, Grant Number LADY_TATA_21_3223). EC is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” (ICREA) of the Generalitat de Catalunya. This work was partially developed at the Centre Esther Koplowitz (CEK, Barcelona, Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  • Nadeu, Ferran
  • Massoni-Badosa, Ramon
  • Ruiz Gil, Sara
  • Marchese, Domenica, 1986-
  • López Bigas, Núria
  • Gut, Ivo Glynne
  • Heyn, Holger
  • Campo, Elias
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high-B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT., This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR-736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundació La Marató de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigación Biomédica en Red Cáncer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovación (PID2020-117185RB-I00 to X.S.P.), the Fundación Asociación Española Contra el Cáncer (FUNCAR-PRYGN211258SUÁR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5 × 1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya. This work was partially developed at the Center Esther Koplowitz (Barcelona, Spain).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7, 12) (q36, p13) infant AML